Company Focus
Galderma
Latest Galderma News
Biotechnology
Swiss skincare specialist Galderma has announced two-year data from a new interim analysis of a long-term extension study investigating the safety and efficacy of Nemluvio (nemolizumab) in moderate-to-severe atopic dermatitis (AD). 9 June 2025
Dermatology News
Insights
Company Spotlight
Abeona Therapeutics is an Ohio-based biotech firm developing novel gene and cell therapies for the treatment of individuals with rare diseases.
Latest News & Features of interest to Galderma
Biosimilars
South Korea’s biosimilar drug developer Samsung Bioepis has announced that the company has entered into a license, development and commercialization agreement with Nipro Corporation for multiple biosimilar candidates including SB17, a ustekinumab biosimilar candidate, in Japan. 9 June 2025
Biotechnology
Swiss skincare specialist Galderma has announced two-year data from a new interim analysis of a long-term extension study investigating the safety and efficacy of Nemluvio (nemolizumab) in moderate-to-severe atopic dermatitis (AD). 9 June 2025
Biotechnology
US biotech Regeneron Pharmaceuticals and French pharma major Sanofi on Saturday presented results from the DISCOVER Phase IV, single-arm, open-label trial assessing Dupixent (dupilumab) in adults and adolescents with moderate-to-severe atopic dermatitis with skin of color. 9 June 2025
Pharmaceutical
The atopic dermatitis market across the seven major markets is forecast to nearly triple in value over the next decade, driven by advances in targeted therapies and a deeper understanding of disease mechanisms. 5 June 2025
Pharmaceutical
Danish dermatology specialist LEO Pharma has appointed Helle Hedegaard Juhl as executive vice president for global people and corporate affairs (GPCA). 4 June 2025
Biotechnology
US clinical-stage biotech Sagimet Biosciences today reported denifanstat met all primary and secondary endpoints in a Phase III clinical trial for the treatment of moderate to severe acne vulgaris conducted by Sagimet’s license partner Ascletis Bioscience in China. 4 June 2025
Biotechnology
Research news last week included Rocket Pharmaceuticals suffering a setback with its Phase II trial of RP-A501, which resulted in a patient death and a US Food and Drug Administration (FDA) hold on the study. Germany’s InflaRx announced it would discontinue development of vilobelimab in a dermatology condition due to futility. Regeneron and Sanofi presented mixed results for itepekimab, leading them to consider the future of the chronic obstructive pulmonary (COPD) therapy. Also of note, Japan’s Otsuka Pharma revealed that the US FDA has accepted its biologics license application (BLA) for sibeprenlimab for review as an immunoglobulin A nephropathy IgAN) treatment. 1 June 2025
Pharmaceutical
Japan’s Intellectual Property High Court has ordered Sawai Pharmaceutical and Fuso Pharmaceutical Industries to pay a total of over 20 billion yen ($138.5 million) in damages for infringing the patent of Toray Industries’ pruritus drug Remitch OD tablets (nalfurafine). 29 May 2025
Biotechnology
German drug developer InflaRx saw its US-traded shares plunge 55% to $0.82 in pre-market activity today, as it announced that the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase III trial for vilobelimab in pyoderma gangrenosum (PG), recommended that the trial be stopped due to futility. 28 May 2025
Biosimilars
Indian biosimilars developer Biocon Biologics, a subsidiary of Biocon Ltd , today announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for its Yesintek, a biosimilar of ustekinumab, which is marketed under the trade name Stelara by us healthcare giant Johnson & Johnson (NYSE: JNJ) . 27 May 2025
Latest In Brief for Galderma
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Latest Dermatology Ones To Watch News
Japanese drugmaker Shionogi is to scale up its pipeline and global ambitions with a deal worth more than $1 billion, buying the pharmaceutical operations of Japan Tobacco, including its US subsidiary Akros Pharma. 8 May 2025
21 February 2025
4 October 2024
18 September 2024
Dermatology Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze